Carditis after COVID-19 vaccination with a messenger RNA vaccine and an inactivated virus vaccine: a case–control study
Annals of internal medicine, 2022•acpjournals.org
Background: Case reports of carditis after BNT162b2 vaccination are accruing worldwide.
Objective: To examine the association of BNT162b2 and CoronaVac (Sinovac) vaccination
with carditis. Design: Case–control study with hospital control participants. Setting: Territory-
wide, public health care database with linkage to population-based vaccination records in
Hong Kong. Patients: Inpatients aged 12 years or older first diagnosed with carditis were
selected as case patients. All other hospitalized patients without carditis were treated as …
Objective: To examine the association of BNT162b2 and CoronaVac (Sinovac) vaccination
with carditis. Design: Case–control study with hospital control participants. Setting: Territory-
wide, public health care database with linkage to population-based vaccination records in
Hong Kong. Patients: Inpatients aged 12 years or older first diagnosed with carditis were
selected as case patients. All other hospitalized patients without carditis were treated as …
Background
Case reports of carditis after BNT162b2 vaccination are accruing worldwide.
Objective
To examine the association of BNT162b2 and CoronaVac (Sinovac) vaccination with carditis.
Design
Case–control study with hospital control participants.
Setting
Territory-wide, public health care database with linkage to population-based vaccination records in Hong Kong.
Patients
Inpatients aged 12 years or older first diagnosed with carditis were selected as case patients. All other hospitalized patients without carditis were treated as control participants. Ten control participants were randomly matched with each case patient by age, sex, and admission date.
Intervention
Vaccination with BNT162b2 or CoronaVac.
Measurements
Incident diagnosis of carditis based on the International Classification of Diseases, Ninth Revision, and elevated troponin levels.
Results
A total of 160 case patients and 1533 control participants were included. Incidence of carditis per 100 000 doses of CoronaVac and BNT162b2 administered was estimated to be 0.31 (95% CI, 0.13 to 0.66) and 0.57 (CI, 0.36 to 0.90), respectively. Multivariable analyses showed that recipients of the BNT162b2 vaccine had higher odds of carditis (adjusted odds ratio [OR], 3.57 [CI, 1.93 to 6.60]) than unvaccinated persons. Stratified by sex, the OR was 4.68 (CI, 2.25 to 9.71) for males and 2.22 (CI, 0.57 to 8.69) for females receiving the BNT162b2 vaccine. The ORs for adults and adolescents receiving the BNT162b2 vaccine were 2.41 (CI, 1.18 to 4.90) and 13.79 (CI, 2.86 to 110.38), respectively. Subanalysis showed an OR of 9.29 (CI, 3.94 to 21.91) for myocarditis and 1.06 (CI, 0.35 to 3.22) for pericarditis associated with BNT162b2. The risk was mainly seen after the second dose of BNT162b2 rather than the first. No association between CoronaVac and carditis with a magnitude similar to that for BNT162b2 was seen.
Limitation
Limited sample size, absence of electrocardiography and other clinical investigative data, and unrecorded overseas vaccination exposure.
Conclusion
Despite a low absolute risk, there is an increased risk for carditis associated with BNT162b2 vaccination. This elevated risk should be weighed against the benefits of vaccination.
Primary Funding Source
Health and Medical Research Fund.
acpjournals.org